published on Clinical Oncology News

San Antonio—To some urologic oncologists, treating only the tumor and not the whole gland in a man with prostate cancer just doesn’t sound right.

“I understand that for many people, the concept of focal therapy for the prostate gives them a visceral disgust, they can hardly say the words,” said Scott Eggener, MD, an associate professor of surgery-urologic oncology and the co-director of the prostate cancer program at the University of Chicago Medicine.

With that high hurdle to jump, Dr. Eggener and the other panelists presented their rationale in a session on partial gland ablation at the 2016 annual meeting of the Society of Urologic Oncology.

Click here to read the full article on ClinicalOncologyNews.com